Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Rating of “Moderate Buy” by Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and twenty have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $312.30.

ALNY has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, March 21st. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research note on Friday, March 21st. Finally, HC Wainwright increased their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. This represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital World Investors increased its stake in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. grew its stake in Alnylam Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock valued at $2,996,296,000 after buying an additional 98,303 shares in the last quarter. Capital Research Global Investors grew its stake in Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ ALNY opened at $271.02 on Friday. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company’s 50 day moving average price is $259.42 and its 200-day moving average price is $260.39. The company has a market capitalization of $35.09 billion, a P/E ratio of -124.89 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.